Thomas R. Staab II
2014
In 2014, Thomas R. Staab II earned a total compensation of $2.1M as Senior Vice President and Chief Financial Officer at BioCryst Pharmaceuticals, a 82% increase compared to previous year.
Compensation breakdown
| Bonus | $62,308 |
|---|---|
| Non-Equity Incentive Plan | $113,747 |
| Option Awards | $974,413 |
| Salary | $399,120 |
| Stock Awards | $583,200 |
| Other | $13,000 |
| Total | $2,145,788 |
Staab received $974.4K in option awards, accounting for 45% of the total pay in 2014.
Staab also received $62.3K in bonus, $113.7K in non-equity incentive plan, $399.1K in salary, $583.2K in stock awards and $13K in other compensation.
Rankings
In 2014, Thomas R. Staab II's compensation ranked 4,228th out of 13,032 executives tracked by ExecPay. In other words, Staab earned more than 67.6% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 4,228 out of 13,032 | 68th |
Division Manufacturing | 1,494 out of 4,966 | 70th |
Major group Chemicals And Allied Products | 488 out of 1,686 | 71st |
Industry group Drugs | 378 out of 1,365 | 72nd |
Industry Biological Products, Except Diagnostic Substances | 64 out of 236 | 73rd |
Source: SEC filing on April 12, 2017.
Staab's colleagues
We found four more compensation records of executives who worked with Thomas R. Staab II at BioCryst Pharmaceuticals in 2014.